Tirzepatide in Connecticut: online providers, prices and license checks
As of November 4, 2026, adults in Connecticut can get compounded tirzepatide or brand Zepbound through online telehealth programs whose prescribers hold a Connecticut license. Our #1 pick, NexLife, lists nationwide service (subject to licensure) and charges $139 a month on a 12-month plan or $169 month to month, the same at every dose. Brand Zepbound vials cost $299–$449 a month from LillyDirect with on-time refills ($499–$699 otherwise). Connecticut Medicaid does not cover GLP-1s for obesity (KFF, January 2026). Before paying, check the prescriber with the Connecticut Medical Examining Board and the pharmacy with the Connecticut Commission of Pharmacy.
Connecticut at a glance
| Adults with obesity (CDC) | 30.4% (2025) |
|---|---|
| Medicaid coverage of GLP-1s for obesity | Does not cover (KFF, Jan 2026) |
| Physician licensing board | Connecticut Medical Examining Board |
| Pharmacy licensing | Connecticut Commission of Pharmacy |
| Program-specific limits we found | None among the programs we reviewed on November 4, 2026 |
30.4% of adults in Connecticut had obesity in 2025, per the CDC — 38th highest of the 47 states with 2025 data. Connecticut Medicaid does not cover GLP-1 medicines for obesity, according to KFF (January 2026); coverage for type 2 diabetes is separate. Self-pay prices below do not depend on Medicaid status.
Who can prescribe tirzepatide to Connecticut residents?
A telehealth clinician who treats you in Connecticut must hold a license recognized in Connecticut. Physicians are licensed by the Connecticut Medical Examining Board; nurse practitioners are licensed by the state board of nursing. You can look up any physician on the board's site or on DocInfo.org, the Federation of State Medical Boards' national search. Ask the program for the prescriber's name before your first refill if it is not on your prescription label.
What Connecticut residents pay in November 2026
The programs we track publish one national price; we have not found a program that prices Connecticut differently. These are the self-pay figures we re-read on the providers' and manufacturers' own pages on November 4, 2026:
| Program | Product | Self-pay price | Read |
|---|---|---|---|
| NexLife (our #1) | Compounded tirzepatide | $139/mo on a 12-month plan; $169 month to month; same price at every dose | Nov 4, 2026 |
| Collective | Compounded tirzepatide | $69/mo + $199 yearly membership (about $86/mo all-in) | Nov 4, 2026 |
| SnagRx | Compounded tirzepatide | $119/mo sale price ($149 in its terms) | Nov 4, 2026 |
| Mondae | Compounded tirzepatide | $126/mo | Nov 4, 2026 |
| Zepbound (LillyDirect) | Brand, FDA-approved | $299 (2.5 mg), $399 (5 mg), $449 (7.5–15 mg with on-time refill) | Nov 4, 2026 |
| Foundayo pill (LillyDirect) | Brand, FDA-approved (orforglipron) | from $149/mo at the lowest dose | Nov 4, 2026 |
See the full compounded tirzepatide price index for every program on file, each with its billing basis and read date, or the most affordable options.
What else affects tirzepatide access in Connecticut?
10.9% of adults in Connecticut reported diagnosed diabetes in 2025, below the U.S. figure of 12.5% and 38th highest of the 50 states and DC in the KFF table built from CDC survey data. That matters for cost: Mounjaro and Ozempic are diabetes drugs, so many people with type 2 diabetes in Connecticut can get brand GLP-1s through insurance rather than paying cash for a compounded version.
742,808 people in Connecticut were enrolled in Medicare in 2024 (KFF). Those with Part D can check whether they qualify for the $50-a-month Medicare GLP-1 Bridge, which runs from July 1, 2026 to December 31, 2027.
State employee health plan, GLP-1s for weight loss in 2026: Covered (FlyteHealth prescriber required) (source dated 2025-08 (FAQ); 2026-05-21 (Comptroller release)).
State actions on compounded GLP-1s in Connecticut
| Date | Who acted | What happened |
|---|---|---|
| December 3, 2025 | Attorney General | Cease-and-desist letters to three weight-loss spas (Danbury, Brookfield, Avon) over claims that compounded injections were FDA-approved or versions of Ozempic/Mounjaro; earlier May 2025 letters warned clinics that marketing compounded GLP-1s may violate CUTPA. |
| May 6, 2026 | Attorney General | Settlements with Made-in-China platform (stop "research grade" GLP-1 sales; $300,000 penalty, suspended after $30,000) and Radiance Medspa of Avon (advertised/prescribed compounded semaglutide/tirzepatide). |
Getting a refrigerated shipment in Connecticut
Compounded tirzepatide usually ships refrigerated. In Connecticut, the practical issue is commuter markets and Northeast winter delivery: commuter schedules, dense suburbs, and winter weather can affect cold-chain delivery and refill timing. Ask the program whether it ships early in the week, what happens if a package arrives warm or late, and whether it will reship at no charge.
Programs serve Connecticut statewide by mail, including Bridgeport, Stamford, New Haven, Hartford, Waterbury and Norwalk.
Checking the pharmacy that fills a Connecticut prescription
Your vial label names the dispensing pharmacy; it should be licensed by the Connecticut Commission of Pharmacy or permitted to ship into Connecticut. Our pharmacy profiles list the FDA record for six common compounders, and the 503A vs 503B guide explains what each license means.
Frequently asked questions about tirzepatide in Connecticut
Does Connecticut Medicaid cover Zepbound or Wegovy for weight loss?
Connecticut Medicaid does not cover GLP-1 medicines for obesity, according to KFF (January 2026); coverage for type 2 diabetes is separate. Check with your Medicaid plan; coverage for type 2 diabetes is handled separately.
How common is obesity in Connecticut?
30.4% of adults in Connecticut had obesity in 2025, per the CDC — 38th highest of the 47 states with 2025 data. Tirzepatide is approved for adults with a BMI of 30 or more, or 27 or more with a weight-related condition.
Can I get tirzepatide online in Connecticut?
Yes. Telehealth programs can prescribe tirzepatide to Connecticut residents when the clinician holds a Connecticut license and the dispensing pharmacy is licensed to ship into Connecticut. Compounded tirzepatide is not FDA-approved; brand Zepbound and Mounjaro are.
How much does tirzepatide cost in Connecticut without insurance?
The same as elsewhere: programs price nationally. As of November 4, 2026, NexLife charges Connecticut residents $139 a month on a 12-month plan or $169 month to month for compounded tirzepatide; Collective lists $69 a month plus a $199 yearly membership. Zepbound vials cost $299–$449 a month through LillyDirect.
How do I check a Connecticut prescriber's license?
Search the clinician's name on the Connecticut Medical Examining Board license lookup, or on DocInfo.org, the Federation of State Medical Boards' national lookup. A nurse practitioner is licensed by the state's board of nursing.
Is compounded tirzepatide legal in Connecticut?
Yes, within federal limits: a state-licensed 503A pharmacy may compound it for an individual Connecticut patient on a prescription. It is not FDA-approved. Check the pharmacy with the Connecticut Commission of Pharmacy.
Nearby states and next steps
Neighbouring state guides: New York, Massachusetts, Rhode Island. Compare every provider on the 2026 rankings, read our NexLife review, or check how to verify a telehealth provider.
Sources
- CDC: Adult obesity prevalence by state, BRFSS 2011–2025
- KFF: Medicaid coverage of and spending on GLP-1s (January 16, 2026)
- FDA: Registered outsourcing facilities
- FDA: Proposal on GLP-1s and the 503B bulks list (April 30, 2026)
- LillyDirect: Zepbound self-pay pricing
- KFF: Adults who report diagnosed diabetes, by state
- KFF: Total Medicare enrollment by state
- Connecticut state employee plan source
- Connecticut: Attorney General (December 3, 2025)
- Connecticut: Attorney General (May 6, 2026)
Informational only, not medical advice. Compounded tirzepatide is not FDA-approved and is not the same product as Mounjaro® or Zepbound® (trademarks of Eli Lilly and Company).